bexarotene has been researched along with Carcinoma, Epidermoid in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Lee, SB; Lubet, RA; Miller, MS; Mirza, SP; Pan, J; Stevenson, ME; Wang, Y; Xiong, D; You, M; Zhang, Q; Zhou, Y | 1 |
| Gudas, LJ; Osei-Sarfo, K | 1 |
| Alden, C; Blumenschein, G; Davis, SE; Herbst, R; Hong, WK; Kim, E; Lee, JJ; Lippman, S; Liu, S; Stewart, D; Tang, XM; Tsao, AS; Wistuba, I | 1 |
| Grandis, JR; Johnson, DE; Lamph, WW; Lango, M; Miller, L; Song, JI; Wentzel, AL; Xi, S | 1 |
| Drenning, SD; Grandis, JR; Hwang, JD; Lamph, WW; Lango, MN; Song, JI; Zeng, Q | 1 |
1 trial(s) available for bexarotene and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate; Tetrahydronaphthalenes | 2012 |
4 other study(ies) available for bexarotene and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Optimized Bexarotene Aerosol Formulation Inhibits Major Subtypes of Lung Cancer in Mice.
Topics: Adenocarcinoma of Lung; Administration, Oral; Aerosols; Animals; Anticarcinogenic Agents; Bexarotene; Carcinoma, Squamous Cell; Disease Models, Animal; Drug Compounding; High-Throughput Nucleotide Sequencing; Humans; Hypercholesterolemia; Lung; Lymphocytes, Tumor-Infiltrating; Mice; Signal Transduction | 2019 |
Retinoids induce antagonism between FOXO3A and FOXM1 transcription factors in human oral squamous cell carcinoma (OSCC) cells.
Topics: Antineoplastic Agents; Bexarotene; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Forkhead Box Protein M1; Forkhead Box Protein O3; Gene Expression; Gene Knockdown Techniques; Histone Deacetylases; Humans; Mouth Neoplasms; Promoter Regions, Genetic; Retinoids; RNA, Messenger; Tretinoin | 2019 |
Responsiveness to the retinoic acid receptor-selective retinoid LGD1550 correlates with abrogation of transforming growth factor alpha/epidermal growth factor receptor autocrine signaling in head and neck squamous carcinoma cells.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Bexarotene; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; ErbB Receptors; Fatty Acids, Unsaturated; Head and Neck Neoplasms; Humans; Receptors, Retinoic Acid; Retinoids; Signal Transduction; Tetrahydronaphthalenes; Transplantation, Heterologous | 2003 |
Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Division; DNA-Binding Proteins; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Receptors, Retinoic Acid; Retinoid X Receptors; Signal Transduction; STAT3 Transcription Factor; Tetrahydronaphthalenes; Trans-Activators; Transcription Factors; Transforming Growth Factor alpha; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |